摘要
目的:分析腹水回输治疗肝硬化腹水对肾血流及肾脏血管活性因子活性的影响。方法:选取2017年1月至2018年12月收治的110例肝硬化腹水患者,以等距随机抽样法分为常规组(采取常规治疗)及回输组(常规基础上实施腹水回输治疗),每组患者各55例,对两组临床疗效进行对比。结果:治疗前两组患者各项指标差异无统计学意义,治疗后两组患者24 h尿量、肾血流量较治疗前升高,其余指标较治疗前下降,回输组患者均优于常规组,差异均有统计学意义(均P<0.05);回输组患者症状消失时间短于常规组,差异有统计学意义(P<0.05)。结论:腹水回输治疗肝硬化腹水疗效理想,能够提高肾血流量以及肾脏血管活性因子活性,值得推广。
Objective:To analyze the effect of ascites in the treatment of cirrhosis and ascites on renal blood flow and renal vasoactive factors.Methods:A total of 110 patients with cirrhosis and ascites admitted to our hospital from January 2017 to December 2018 were enrolled.The patients were routinely randomized and randomly divided into routine treatment group and ascites reinfusion on the basis of ascites reinfusion.There were 55 cases in each group,and the clinical effects of the two groups were compared.Results:There were no significant differences in B-ultrasound,abdominal circumference,body mass,24-hour urine volume,endotoxin,thromboxane,leukotriene,liver function,inflammatory factors,renal vasoactive factor activity,and renal blood flow before treatment.24 hours after treatment,urine volume and renal blood flow were higher than before treatment,and other indexes were lower than before treatment.The ascites return group was superior to the conventional group,the difference was statistically significant(P<0.05);ascites return group symptoms The disappearance time was shorter than that of the conventional group,and the difference was statistically significant(P<0.05).Conclusion:Ascites reinfusion is an effective treatment for cirrhosis and ascites,which can improve renal blood flow and renal vasoactive factor activity.It is worthy of popularization in clinical treatment work in the future.
作者
秦维
祝素平
郑艳丽
霍玉玲
王丹
QIN Wei;ZHU Su-ping;ZHENG Yan-li(The Fourth Liver Departments of Baoding Infectious Diseases Hospital(Baoding Hebei,071000)China)
出处
《中西医结合肝病杂志》
CAS
2020年第4期307-310,共4页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
关键词
肝硬化腹水
肾血流
肾脏血管活性因子
腹水回输
cirrhosis ascites
renal blood flow
renal vasoactive factor
ascites return